Skip to main content
LigaChem Biosciences Inc. logo

LigaChem Biosciences Inc. — Investor Relations & Filings

Ticker · 141080 ISIN · KR7141080002 KO Professional, scientific and technical activities
Open in API
Filings indexed 290 across all filing types
Latest filing 2026-04-29 Board/Management Inform…
Country KR South Korea
Listing KO 141080

About LigaChem Biosciences Inc.

https://ligachembio.com/

LigaChem Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative medicines. Leveraging its core expertise in medicinal chemistry, the company focuses on developing Antibody-Drug Conjugates (ADCs), immuno-oncology drugs, and small molecules. A key asset is its proprietary, next-generation ADC platform technology, engineered to overcome the limitations of conventional ADC technologies. The company's pipeline includes multiple programs targeting oncology, as well as other therapeutic areas such as antibiotics and anti-fibrotics. LigaChem Biosciences actively pursues global drug development through strategic partnerships, including co-development and licensing agreements with international pharmaceutical companies.

Recent filings

Filing Released Lang Actions
대표이사변경
Board/Management Information Classification · 1% confidence The document announces the resignation of the former CEO and the appointment of a new representative director, including board resolution dates and executive’s career details. This is clearly an announcement of changes in senior management, fitting the Board/Management Information category.
2026-04-29 Korean
수시공시의무관련사항(공정공시) (대표이사 변경 예정)
Board/Management Information Classification · 1% confidence The document is a Korean ad hoc disclosure announcing a planned change of CEO (대표이사 변경 예정). It provides details of the outgoing and incoming CEO, their backgrounds, and the board selection procedure. This clearly falls under announcements of changes in the company's board of directors or senior management rather than the actual report. Therefore it is classified as Board/Management Information (MANG).
2026-04-28 Korean
투자판단관련주요경영사항(임상시험계획승인신청) (CLDN18.2 항체-약물 접합체 (ADC) LCB02A의 제 1/2상 임상시험의 미국 임상시험계획(IND) 승인 신청)
Regulatory Filings Classification · 1% confidence The document is a Korean-language disclosure of a significant corporate event – an application to the U.S. FDA for clinical trial approval (IND) for an antibody-drug conjugate. It is not an annual or interim financial report, earnings release, governance or management discussion, nor a shareholder vote or dividend notice. It is a material event notification typical of regulatory announcements under exchange rules. Hence it falls under the general “Regulatory Filings” category (RNS).
2026-04-14 Korean
주식매수선택권행사
Share Issue/Capital Change Classification · 1% confidence The document is a formal announcement of employee stock option exercises and the resulting issuance of new shares, detailing the number of shares issued, exercise dates, strike prices, and remaining option balances. This constitutes a change in the company’s capital structure through new share issuance under stock options. It is not merely a repurchase (POS), a director trade (DIRS), or a simple report publication notice (RPA), but a direct announcement of a share issue/capital change. Therefore, it fits the Share Issue/Capital Change category (SHA).
2026-04-08 Korean
투자판단관련주요경영사항 (신규 기전 신약 연구개발을 위한 기술도입 계약 체결)
Regulatory Filings Classification · 1% confidence The document is a Korean disclosure of a material contract (technology licensing agreement for new drug R&D), providing detailed terms, counterparties, payment structure, and risk factors. It is not an Annual Report, interim report, earnings release, call transcript, management change notice, dividend, share issuance, insider transaction, M&A, or other defined category. Therefore it falls into the fallback “General Regulatory Filing” category.
2026-04-06 Korean
투자판단관련주요경영사항 (신규 항체-약물 결합체(ADC) 연구개발을 위한 공동연구 및 항체 기술도입 계약 해지)
Regulatory Filings Classification · 1% confidence The document is a Korean regulatory disclosure (“투자판단 관련 주요경영사항”) announcing the termination of a joint R&D and antibody technology licensing contract. It is not a financial report (10-K, IR), not an earnings release (ER), not a board change (MANG), not a dividend notice (DIV), nor a director’s dealing (DIRS), nor an M&A or financing update. It is a general material event disclosure mandated by the exchange, so it falls into the fallback category of Regulatory Filings (RNS).
2026-04-02 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.